Histamine H₃ Receptor Integrates Peripheral Inflammatory Signals in the Neurogenic Control of Immune Responses and Autoimmune Disease Susceptibility

Dimitry N. Krementsov¹⁹, Emma H. Wall¹⁹, Rebecca A. Martin¹, Meenakumari Subramanian¹, Rajkumar Noubade¹*, Roxana Del Rio¹, Gary M. Mawe¹, Jeffrey P. Bond¹, Matthew E. Poynter¹, Elizabeth P. Blankenhorn², Cory Teuscher¹³, *E-mail: C.Teuscher@uvm.edu

¹Department of Medicine, Immunobiology Program, University of Vermont, Burlington, Vermont, United States of America, ²Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America, ³Department of Pathology, University of Vermont, Burlington, Vermont, United States of America

Abstract
Histamine H₃ receptor (Hrh3/H₃R) is primarily expressed by neurons in the central nervous system (CNS) where it functions as a presynaptic inhibitory autoreceptor and heteroreceptor. Previously, we identified an H₃R-mediated central component in susceptibility to experimental allergic encephalomyelitis (EAE), the principal autoimmune model of multiple sclerosis (MS), related to neurogenic control of blood brain barrier permeability and peripheral T cell effector responses. Furthermore, we identified Hrh3 as a positional candidate for the EAE susceptibility locus Eae8. Here, we characterize Hrh3 polymorphisms between EAE-susceptible and resistant SJL and B10.S mice, respectively, and show that Hrh3 isoform expression in the CNS is differentially regulated by acute peripheral inflammatory stimuli in an allele-specific fashion. Next, we show that Hrh3 is not expressed in any subpopulations of the immune compartment, and that secondary lymphoid tissue is anatomically poised to be regulated by central H₃R signaling. Accordingly, using transcriptome analysis, we show that, inflammatory stimuli elicit unique transcriptional profiles in the lymph nodes of H₃RKO mice compared to WT mice, which is indicative of negative regulation of peripheral immune responses by central H₃R signaling. These results further support a functional link between the neurogenic control of T cell responses and susceptibility to CNS autoimmune disease coincident with acute and/or chronic peripheral inflammation. Pharmacological targeting of H₃R may therefore be useful in preventing the development and formation of new lesions in MS, thereby limiting disease progression.

Introduction
Multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system (CNS), is the most common disabling neurologic disease of young adults and adolescents affecting ~350,000 individuals in the United States and more than 1 million individuals worldwide [1]. The etiopathogenesis of MS is largely unknown; however, it involves both genetic and environmental factors [2,3,4]. The spectrum of clinical courses in MS is diverse and includes relapsing/remitting (R/R), primary progressive, secondary progressive, and relapsing remaniscent MS [5]. Additional subtypes based on severity include benign [6] and malignant MS [7,8]. The pathologic lesions that best correlate with acute clinical exacerbations of disease feature foci of inflammation associated with active myelin degradation and phagocytosis and partial axonal preservation. Axonal injury and loss, however, occur to varying degrees in all lesions and in normal-appearing white and grey matter, and axon loss is a major correlate for permanent clinical deficits. Structurally, MS lesions show characteristic features which include demyelination, loss of oligodendrocytes, preferential destruction of thin caliber axons, impaired remyelination and astrocytic gliosis [9].

Research into the mechanisms underlying neuroinflammatory reactions in MS is largely driven by two hypotheses [10]. The immune-initiated hypothesis contends that autoreactive T cells generated in the periphery gain entry to the CNS where they elicit an inflammatory cascade that results in injury to previously normal neural tissues. In contrast, the neural-initiated disease
hypothesis posits that events within the CNS initiate the process and that autoimmune responses are secondary. Previously, in the course of our studies examining the role of histamine and histamine receptors in experimental autoimmune encephalomyelitis (EAE) – often used to model aspects of these essentially conflicting hypotheses – we identified histamine H3 receptor (Hrh3/H3R) as a gene that potentially unites these opposing theories functionally [11].

H3R is expressed presynaptically where it is an inhibitory autoreceptor (inhibits release of HA from histaminergic neurons) and heteroreceptor (inhibits release of other neurotransmitters such as acetylcholine, noradrenaline, dopamine, 5-HT, GABA, and glutamate from non-histaminergic neurons) [12]. Absence of presynaptic inhibition results in failure to limit neurotransmitter release, increased postsynaptic activity, and neurotransmitter spillover [13]. Our studies revealed the existence of an H3R-mediated central component in susceptibility to EAE related to neurogenic control of blood brain barrier (BBB) permeability and expression of cytokines and chemokines, and their receptors, by peripheral T cells. Subsequently, H3R was shown to similarly regulate neuroinflammation in cerebral malaria, with H3R-deficiency correlating with increased BBB permeability and altered T cell phenotypes [14]. Moreover, we identified Hrh3, which under normal physiologic conditions plays a role in regulating body weight [15], as a positional candidate gene for Eae8, a quantitative trait locus (QTL) controlling EAE susceptibility and associated weight loss [16,17,18].

In this study, we provide functional characterization of a G293D polymorphism in the third intracellular domain of H3R associated with G-i/o and beta-arrestin coupling to second messenger signaling pathways [19,20,21] that distinguishes EAE-susceptible SJL mice and EAE-resistant B10.S mice. We also demonstrate allele-specific differential expression of Hrh3 isoforms in the CNS in response to peripheral inflammatory stimuli, i.e., adjuvants used to elicit disease. Using a transcriptomics approach, we further show that the absence of H3R signaling in the CNS
significantly alters early responses to such stimuli at the level of the lymph node (LN). Taken together, our results provide additional support for Hrk as a gene central to a neural reflex [22,23,24] controlling peripheral immune responses and EAE susceptibility, and as a positional candidate gene for Ead6. Importantly, our findings provide a functional framework unifying the immune- and neural-initiated models of MS pathogenesis, and provide insight into the mechanisms whereby gene-by-environmental stimuli may influence the long term progression and spectrum of clinical disease courses seen in MS [25].

Results and Discussion

Characterization of Hrh3 Polymorphism Distinguishing EAE-susceptible SJL and EAE-resistant B10.S Mice

Previously, using B10.S.SJL-Eae8 congenic mice, we identified Hrk as a positional candidate gene for Ead6, a QTL controlling EAE susceptibility and associated weight loss [16,17,18]. Given that EAE-susceptible mouse strains experience weight loss with the onset of EAE [26] and that H2RKO mice manifest changes in weight and energy expenditure [27], we hypothesized that an Hrh3 polymorphism distinguishing EAE-resistant B10.S and EAE-susceptible SJL mice may underlie Ead6. As a first test of this hypothesis, we undertook cDNA sequencing of the two alleles to identify coding region variants. A single missense mutation at position 878 (G to A) leading to a change from glycine to aspartic acid at residue 293 (G293D in SJL) was identified (Fig. 1). An examination of 18 different inbred strains of mice using restriction fragment length polymorphism (RFLP) analysis confirmed the existence of two alleles segregating among the various inbred strains (Fig. 1).

The G293D substitution resides within the third intracellular (IC) loop which couples H3R to Gi/o and beta-arrestin second messenger signaling pathways [19,20,21]. The G293D substitution in H3R is analogous to the amino acid substitutions recently identified within the third IC domain of H2R underlining Bphs, a shared immunopathology disease gene controlling Bordetella pertussis-induced sensitivity to histamine, EAE, and autoimmune orchitis [28,29,30]. Importantly, a A280V missense mutation within the third IC loop of the human H3R gene has been reported in multiple system atrophy (Shy-Drager Syndrome), a rare neurodegenerative disease [31] and as a risk factor for migraine [32].

To assess the functionality of the G293D polymorphism, we expressed the two alleles and compared the pharmacologic properties of the H3R ligands R-α-methylhistamine (RAM-HA) and Imetit in a radioligand binding assay, a GTPγS-binding assay, and a ligand-induced Ca2+ mobilization assay (Fig. 2A–C). Overall, no significant difference in either receptor affinity or activity was detected, suggesting that the G293D polymorphism does not alter the function of the protein per se. However, these results do not exclude the possibility that an Hrk3 isoform expression polymorphism may underlie Ead6, since the assays described above are limited to utilizing full length Hrk3 cDNA expressed under a heterologous promoter.

Differential Hrh3 Isoform Expression in SJL and B10.S Mice in Response to Peripheral Inflammatory Stimuli

Multiple H3R isoforms have been described for humans, rats, and mice. In the human, H3R isoforms demonstrate differences in pharmacologic activity [33,34,35]. Many of these isoforms differ from the full length transcript by a variable-length deletion in the third IC loop. Importantly, isoform variation in this region results in differences in H3R functional activity. For example, an 80

Figure 2. Pharmacological comparison of Hrh3 allele functionality. (A) Characterization of H3R and H3RG293D using radioligand binding assays. Plasmids carrying Hrh3 cDNA for the indicated alleles were transiently transfected into COS-7 cells. Cell membranes from transfected cells were used in radioligand binding assays with 3H-RAM-HA as the tracer in the presence of various concentrations of unlabeled RAM-HA and Imetit as the competitors (see Materials and Methods). Membranes from mock transfected COS-7 cells were used as the negative controls (Cntl). (B) Functional comparison of H3R and H3RG293D in GTPγS binding assays. Membranes from CHO cells transiently expressing H3R cDNA for the indicated alleles were stimulated with various concentrations of RAM-HA and Imetit in the presence of 35S-GTPγS as the tracer (see Materials and Methods). Membranes from mock transfected CHO cells were used as the negative controls (Cntl). (C) Functional comparison of H3R and H3RG293D Ca2+ mobilization assays. 293T cells co-expressing Gq5 and H3R or H3RG293D were stimulated with different concentrations of RAM-HA and Imetit. The ligand-stimulated Ca2+ mobilization was monitored using a FLIPR instrument (Molecular
amino acid deletion at the third IC loop of human H₃R confers increased constitutive activity [21]. In the rat, 32 and 48 amino acid deletions, which in the mouse encompasses the G293D polymorphism, result in changing H₃R’s efficiency in G protein coupling to second messenger signaling pathways [19,20]. Consequently, these deletions result in increased constitutive activity, similar to the 80 amino acid deletion in the human H₃R.

In our previous EAE study, H₃RKO mice immunized for the induction of EAE exhibited increased BBB permeability on D4 post-immunization, significantly earlier than the appearance of inflammatory cells in the CNS [11]. This finding supports a role for events predicted by the neural-initiated disease hypothesis, which posits that events within the CNS initiate the disease process and influence subsequent autoimmune responses. We reasoned therefore that differential expression of H₃R isoforms in response to inflammatory stimuli i.e., adjuvants/pain/danger signals etc., may be important in neurogenic control of disease susceptibility in SJL and B10.S mice. In this regard, both pertussis toxin (PTX) [36] and complete Freund’s adjuvant (CFA) [37] lead to increased BBB permeability and systemic exposure to lipopolysaccharide (LPS) directly disrupts endothelial cell barrier functions [38] including BBB transport of amyloid proteins [39,40], which have recently been shown to suppress EAE severity [41]. Moreover, advances in neuroscience and immunology have established the anatomical and cellular basis for bidirectional communication between the nervous system and immune systems [22]. To explore the possibility that inflammatory stimuli can impact H₃R isoform expression, H₃Risoform expression was studied by RT-PCR using forebrain tissue from untreated SJL and B10.S mice, or at D1 and D10 after immunization with proteolipid protein peptide 139–151 (PLP139-151) + complete Freund’s adjuvant (CFA)+pertussis toxin (PTX), or with each of the respective components of the adjuvants used to induce disease, CFA, PTX, or CFA+PTX. Isoform-specific RT-PCR primers were designed based on the 3 published rat isoform sequences; thus detecting murine orthologs of the rat H₃R are complex and impact a variety of phenotypes including weight, metabolism, cognition/memory, arousal, sensory-motor activity, thermoregulation, and inflammatory and non-inflammatory pain [44]. Many, if not all of these are dysregulated in MS [45,46,47,48]. For example, ~50% of MS patients experience one or more types of pain simultaneously, occurring at any point during the disease course [45]. In SJL/J mice with either EAE or Thelier’s murine encephalomyelitis virus (TMEV) induced demyelination, a viral model of MS, dysregulated pain sensation, including allodynia and hyperalgesia, is observed [49,50,51]. In EAE, these effects involve dysregulation of the glutamatergic system [50] in which H₃R is a presynaptic heteroreceptor, negatively modulates glutamate release [44]. Similarly, cognitive impairment which is common in MS [46,52] is also seen in EAE in association with dysregulated glutamatergic and GABAergic transmission [53].

Histamine H₃ Receptor Controls Immune Responses

In our earlier EAE study [11], and in a study on cerebral malaria in mice [14], it was proposed that H₃R plays a role in neurogenic control of T cell effector responses. As such, H₃R would serve as a key gene in the elaborate interactions between the brain and the immune systems [54] comprising a neural inflammatory reflex [22,23,24]. To exclude the possibility that H₃R is influencing immune responses directly through its expression in either secondary lymphoid tissues and/or hematopoietic cells including T cells, we examined its expression in the spleen and LN of naive animals, and by macrophages, mast cells, neutrophils, bone marrow-derived dendritic cells, B cells (B220+), effector CD8+ (TCR+CD8+CD44+), naive CD4+ (TCR+CD4+CD25−CD62L+CD44+CD1d-tetramer+), memory CD4+ (TCR+CD4+CD25−CD62L+CD44+CD1d-tetramer+), NKT (CD1d tetramer+), and Treg cells (TCR+CD4+Fasp3+) by RT-PCR. mRNA for any of the known H₃R isoforms was undetectable in both whole spleen and LN, as well as in all cells of
the innate and adaptive immune systems studied. These data are also predicted by the neural-initiated disease hypothesis and identify H₃R as a key CNS intermediate in a neural inflammatory reflex influencing T cell effector responses and susceptibility to EAE, presumably through innervation of secondary lymphoid tissues.

To confirm the innervation of mouse spleen and LN, we employed immunohistochemistry using neuronal-specific enolase (NSE), a pan-neuronal marker [55]. In the spleen, dense innervation was observed, particularly around the vasculature, as previously reported [56] (Fig. 5A and B). However, in contrast to what has been reported for the LNs of other species, where nerve fibers have been shown to branch into the parenchyma in paracortical and cortical regions [57], only sparse innervation was detected in the mouse LN. This was primarily located in the capsular and subcapsular sinus (SCS) (Fig. 5C and D) and absent from the parenchyma. This pattern of innervation was similar regardless of the age of the mouse or LN location (data not shown). Although in our hands the mouse LN lacked innervation in traditional T and B cell zones, the finding of innervation in the capsular and SCS is nevertheless consistent with the finding that particulate antigens and pathogens arriving via the lymphatics are retained in the SCS of mouse LN [58,59,60,61,62], and that naive T cells can relocalize to the SCS in response to infection [63]. Moreover, SCS macrophages can present antigen to B cells [59,61,62], in line with their ability to retain antigen on their surface, rather than internalize and degrade it [64,65]. Additionally, SCS macrophages have been shown to be specialized APCs, which in conjunction with non-cognate B cells deliver opsonized antigens to germinal centers thereby promoting affinity maturation [66].

Taken together, our results support a role for innervation of secondary lymphoid tissues in H₃R-mediated neurogenic control

---

**Figure 3. Hrh3 isoform expression is influenced primarily by strain.** Expression levels were determined by real time PCR using mRNA isolated from perfused forebrains on D1 (A) and (C) and D10 (B) and (D) post-injection with either CFA, PTX, CFA+PTX or PLP+CFA+PTX, as described in Materials in Methods (n = 4–8). Data were analyzed by two-way ANOVA for effect of treatment and strain. doi:10.1371/journal.pone.0062743.g003
Figure 4. Differential Hrh3 isoform expression in B10.S and SJL mice in response to peripheral inflammatory stimuli. (A) Hrh3a expression in the forebrain of B10.S and SJL mice (n = 20), as determined by qRT-PCR (see Materials and Methods), either untreated, or D1 and D10 post-treatment. (B) Hrh3c expression in the forebrain of B10.S and SJL mice, untreated, or D1 and D10 post-treatment. Data were analyzed by two-way ANOVA for effect of treatment and strain.

doi:10.1371/journal.pone.0062743.g004

Figure 5. Spleen and LN are innervated at physically relevant locations. Fixed, frozen sections of spleen (A and B) and pancreatic LN (C and D) from C57BL/6 mice were stained with anti-NSE antibody and visualized with Cy3-conjugated secondary antibody. (A) and (B), 200× magnification; (C) and (D), 400× magnification. Figure labels: v, vascular plexus; scs, subcapsular sinus; p, parenchyma.

doi:10.1371/journal.pone.0062743.g005
of immune responses. Nevertheless, it is worth noting that H₃R-mediated neurogenic control of immune responses via the hypothalamic-pituitary-adrenal axis cannot be completely excluded in EAE since H₃R agonist stimulated release of adrenocorticotrophic hormone (ACTH) from the mouse pituitary tumor cell line, AtT-20, can be blocked by first generation H₃R antagonists [67,68]. However, a recent study brings into question the role of H₁R in regulating ACTH release. Using a highly selective second generation antagonist capable of pharmacologically discriminating H₁R and H₃R indicates that H₁R rather than H₃R regulates ACTH release from AtT-20 cells [69].

H₃R Signaling Regulates Gene Expression in LN

Given the findings that H₃R negatively regulates the development of EAE, a T cell-mediated autoimmune disease, that antigen-specific CD4⁺ T cells from H₃RKO animals demonstrate a unique effector profile [11,14], and that the microenvironments of secondary lymphoid tissues are anatomically poised to be subjected to H₁R mediated neurogenic control, we evaluated the possibility that central H₁R signaling modulates gene expression in the LN under basal conditions and in early responses to peripheral stimuli. To this end, we utilized microarrays to examine baseline gene expression in the LN of untreated WT and H₃RKO mice. Because changes in Hrh3 isoform expression occur within 24 hours of exposure to peripheral inflammatory stimuli (Fig. 4), we also examined gene expression at 24 hours following the administration of the two adjuvants used to induce EAE, CFA alone or in combination with PTX.

Relatively few differences in gene expression between WT and H₃RKO mice were observed in the LN at baseline (9 genes, Table 1). However, most of these genes were of immunological relevance, as identified by Ingenuity® Pathway Analysis (IPA). Several immunoglobulin (Ig) genes were downregulated in H₃RKO LN, whereas S100 calcium-binding proteins A8 and A9 (S100a8 and S100a9) were upregulated. The latter play an important role in inflammatory processes, and are upregulated during MS and EAE [70].

CFA treatment resulted in 13 differentially expressed genes between WT and H₃RKO LN (Table 2), many of which were also associated with inflammatory responses. Similar to baseline, several Ig genes remained lower in H₃RKO LN after CFA treatment.

The greatest differences in gene expression between WT and H₃RKO LN were observed after treatment with CFA+PTX, the EAE immunization protocol that elicits increased disease severity in H₃RKO mice compared to WT. There were 29 genes differentially expressed between the strains (Table 3). Consistent with increased EAE severity, the results of IPA revealed that many of the differentially expressed genes were involved in inflammation, with a Z-score clearly indicative of an exaggerated inflammatory/immune response in the LNs of H₃RKO animals following exposure to CFA+PTX (Tables 4 and 5). Most genes associated with inflammatory functions were overexpressed in H₃RKO animals, including Ig genes, which were expressed at lower levels at baseline, and S100a8 and S100a9, which were expressed at higher levels at baseline. We selected three pro-inflammatory genes, S100a8, pro-platelet basic protein/chemokine (C-X-C motif) ligand 7 (Ppbp), and myeloperoxidase (Mpo), all of which were expressed at higher levels in H₃RKO LN after CFA+PTX treatment (Ppbp was also overexpressed in H₃RKO LN after CFA treatment), for validation by qRT-PCR in a series of independent experiments. We confirmed that S100a8 and Mpo were expressed at significantly higher levels in H₃RKO LN, while expression of Ppbp showed an increase that did not reach statistical significance (Fig. 6A). Furthermore, we also confirmed downregulation of Mup1, a gene that was under-expressed in H₃RKO LN (Fig. 6B). Interestingly, S100a8, Mpo, and Ppbp are differentially expressed in the liver of CBA and BALB/c mice in response to Schistosoma infection, with higher expression correlating with more severe pathological outcome [71]. Taken together, given the exaggerated expression of inflammation-related genes in H₃RKO LN, these results are consistent with negative regulation of peripheral immune responses by central H₁R signaling.

In summary, our studies suggest that an Hrh3 isoform expression polymorphism regulates neurogenic control of EAE and T cell effector responses in mice, and is a potential functional candidate polymorphism underlying Eae9. Moreover, our data, predicted by the neural-initiated disease hypothesis, identify H₁R as a key intermediate in a neural immune reflex [22,23,24] integrating peripheral inflammatory signals in the neurogenic control of disease susceptibility and T cell effector responses. Importantly, our findings which functionally unite the opposing neural-initiated and immune-initiated theories underlying neuroinflammatory reactions in MS provide potential insight into the mechanisms

| Gene Expression was determined by microarray analysis. The criterion for differential expression was set at p<0.05 and signed fold change >2. Fold change (FC) indicates the change in expression in H₃RKO LN relative to WT. |
|---|
| Table 1. Genes differentially expressed in WT vs. H₃RKO LN at baseline. |
| Gene | p-value | FC | Symbol | Entrez Gene Name |
|---|---|---|---|---|
| major urinary protein 1 | 1.03E-03 | −10.1 | Mup1 | 1 |
| immunoglobulin heavy constant gamma 1 (G1m marker) | 8.11E-03 | −2.70 | IGHG1 | 1 |
| immunoglobulin heavy constant mu | 3.99E-02 | −2.57 | IGHM | 1 |
| resistin | 7.18E-03 | −2.37 | RETN | 1 |
| complement factor D (adipsin) | 3.16E-03 | −2.14 | CFD | 1 |
| formyl peptide receptor 2 | 2.46E-03 | 2.07 | FPR2 | 1 |
| versican | 2.36E-02 | 2.10 | VCAN | 1 |
| C-type lectin domain family 4, member D | 1.17E-02 | 2.32 | CLEC4D | 1 |
| S100 calcium binding protein A8 | 1.18E-02 | 2.90 | S100A8 | 1 |
| S100 calcium binding protein A9 | 2.36E-02 | 2.10 | VCAN | 1 |
| S100 calcium binding protein A9 | 2.46E-03 | 2.07 | FPR2 | 1 |
| S100 calcium binding protein A9 | 3.16E-03 | 2.10 | VCAN | 1 |
| S100 calcium binding protein A9 | 8.11E-03 | 2.07 | FPR2 | 1 |
| S100 calcium binding protein A9 | 1.03E-03 | 2.07 | FPR2 | 1 |

PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e62743
Table 2. Genes differentially expressed in WT vs. H3RKO LN after CFA treatment.

| p-value | FC    | Symbol | Entrez Gene Name |
|---------|-------|--------|-----------------|
| 2.09E-03 | -3.39 | IGHA1  | immunoglobulin heavy constant alpha 1 |
| 1.21E-02 | -3.14 | IGHG1  | immunoglobulin heavy constant gamma 1 (G1m marker) |
| 7.87E-03 | -2.58 | IGHM   | immunoglobulin heavy constant mu |
| 1.26E-02 | -2.52 | Mup1   | major urinary protein 1 |
| 4.42E-02 | -2.43 | GDA    | guanine deaminase |
| 4.65E-02 | 2.04  | RBP4   | retinol binding protein 4, plasma |
| 6.68E-02 | 2.12  | PCOLCE2| procollagen C-endopeptidase enhancer 2 |
| 4.82E-02 | 2.34  | NPR3   | natriuretic peptide receptor C/guanylate cyclase C |
| 2.54E-02 | 2.61  | Aldha17 | aldehyde dehydrogenase family 1, subfamily A7 |
| 1.15E-02 | 2.82  | PPBP   | pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) |
| 3.39E-03 | 3.05  | TMEM458| transmembrane protein 45B |
| 2.48E-02 | 3.23  | NNAT   | neuronatin |
| 3.11E-02 | 5.92  | Xlr3c  | X-linked lymphocyte-regulated 3C |

Gene expression was determined by microarray analysis. The criterion for differential expression was set at p<0.05 and signed fold change >2. Fold change indicates the change in expression in H3RKO LN relative to WT. doi:10.1371/journal.pone.0062743.t002

whereby gene-by-environmental stimuli may determine the long term progression and spectrum of clinical disease courses seen in MS [25] associated with subtle changes in BBB integrity preceding inflammatory lesions [72,73]. Pharmacologic targeting of H3R may therefore be useful in preventing the development and formation of new lesions in MS, thereby significantly limiting the progress of the disease.

Materials and Methods

Animals

C57BL/6J, B10.S/SgMcdJ and SJL/J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). B6.129P2-Hrh3tm1Twl mice [74] (H3RKO), originally held at Johnson and Johnson Pharmaceutical Research and Development (San Diego, CA) were maintained at the University of Vermont (Burlington, VT). B10.S.eae8SJL mice were generated by marker assisted selection using informative microsatellite markers spanning the eae8 interval [11]. Animals were backcrossed for ten generations at which point they were intercrossed and subsequently fixed as a homozygous interval-specific congenic line. All animals were maintained under specific pathogen free conditions on a 12:12 light dark cycle and were fed Purina mouse pellets (Ralston-Purina, St. Louis, MO) and water ad libitum. The experimental procedures performed in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Vermont; IACUC protocol number 08-034, approved November 9, 2007. Guinea pig samples were obtained in a previously published study [75].

Identification of Polymorphisms in Hrh3

Total RNA from SJL/J and B10.S/SgMcdJ was isolated from adult spleen. cDNAs were PCR amplified using Taq polymerase and specific primer pairs flanking the mRNA coding region of Hrh3. The amplified fragments were cloned and at least three clones for each PCR fragment were sequenced from both insert termini. A single nucleotide polymorphism at position 878 (G→A) leading to a single amino acid change from glycine to asparagine at residue 293 (G293D) in the predicted sequence of H3R was identified between B10.S/SgMcdJ and SJL/J allele. Multiple
sequence alignment was done using the MultAlign website [63]. Rat Hrh3 sequence was obtained from NCBI, accession number NP_445958.

To detect the 878 (G→A) Hrh3 SNP in different inbred strains RFLP was used. oligonucleotide primers flanking the 878 (G→A) SNP were designed: forward primer: 5′-CAAGACGGGCTGTTCGG-3′;

| Table 3. Genes differentially expressed in WT vs. H3RKO LN after CFA+PTX treatment. |
|---|---|---|---|
| p-value | FC | Symbol | Entrez Gene Name |
| 1.75E-03 | -12.3 | Mup1 | major urinary protein 1 |
| 3.24E-03 | -2.90 | CFD | complement factor D (adipsin) |
| 4.97E-02 | -2.83 | FOXA1 | forkhead box A1 |
| 1.03E-02 | -2.76 | RETN | resistin |
| 1.24E-02 | -2.36 | Serpin3k | serine (or cysteine) peptidase inhibitor, clade A, member 3K |
| 8.85E-03 | -2.27 | H19 | H19, imprinted maternally expressed transcript |
| 6.27E-03 | -2.27 | STK31 | serine/threonine kinase 31 |
| 1.42E-03 | -2.14 | ITIH4 | inter-alpha (globulin) inhibitor H4 |
| 3.17E-02 | -2.13 | CITED1 | Cbp/p300-interacting transactivator |
| 5.21E-03 | -2.06 | ADRB3 | adrenergic, beta-3, receptor |
| 3.12E-02 | 2.02 | IGHG1 | immunoglobulin heavy constant gamma 1 |
| 3.42E-02 | 2.04 | FOS | FBJ murine osteosarcoma viral oncogene homolog |
| 1.43E-02 | 2.25 | ACOT2 | acyl-CoA thioesterase 2 |
| 4.61E-02 | 2.32 | IGHM | immunoglobulin heavy constant mu |
| 1.76E-02 | 2.39 | SLPI | secretory leukocyte peptidase inhibitor |
| 3.53E-02 | 2.39 | PRTN3 | protease inhibitor 3 |
| 1.85E-02 | 2.42 | ELANE | elastase, neutrophil expressed |
| 4.37E-02 | 2.60 | IGHA1 | immunoglobulin heavy constant alpha 1 |
| 2.41E-02 | 2.62 | Beta-s | hemoglobin subunit beta-1-like |
| 2.04E-03 | 2.75 | CTSG | cathepsin G |
| 4.33E-02 | 2.79 | Ngp | neutrophil granule protein |
| 2.46E-02 | 2.80 | S100A8 | S100 calcium binding protein A8 |
| 4.39E-02 | 3.14 | Igk-v19-14 | immunoglobulin kappa variable 6-14 |
| 1.15E-02 | 3.31 | Aco1 | acyl-CoA thioesterase 1 |
| 1.64E-02 | 3.48 | S100A9 | S100 calcium binding protein A9 |
| 1.57E-02 | 3.80 | MPO | myeloperoxidase |
| 4.90E-03 | 4.96 | PPBP | pro-platelet basic protein (chemokine [C-X-C motif] ligand 7) |

Gene expression was determined by microarray analysis. The criterion for differential expression was set at p<0.05 and signed fold change >2. Fold change indicates the change in expression in H3RKO LN relative to WT. doi:10.1371/journal.pone.0062743.t003

| Table 4. Top biological pathways associated with changes in inflammation-associated gene expression in H3RKO vs. WT LN after CFA+PTX treatment. |
|---|---|---|---|---|---|
| Category | p-value | Functions Annotation | PAS* | z-score | Molecules |
| Inflamm. Response | 2.57E-07 | inflammatory response | Increased | 2.24 | 9 |
| Inflamm. Response | 9.19E-08 | cell movement of neutrophils | Increased | 2.13 | 7 |
| Inflamm. Response | 1.11E-06 | chemotaxis of neutrophils | | 1.84 | 5 |
| Inflamm. Response | 8.32E-08 | immune response | | 1.76 | 13 |
| Inflamm. Response | 1.63E-06 | adhesion of neutrophils | | 1.69 | 4 |
| Inflamm. Response | 4.53E-07 | cell movement of phagocytes | | 1.63 | 8 |
| Inflamm. Response | 2.31E-07 | Inflammation | | 0.30 | 8 |
| Inflamm. Response | 1.91E-07 | activation of leukocytes | | 0.15 | 9 |

Results of IPA run on genes differentially expressed between WT and H3RKO LN after CFA+PTX treatment. The top 8 associated biological pathways are shown. *PAS, predicted activation state. doi:10.1371/journal.pone.0062743.t004
reverse primer: 5’-TCACGATGATAGCCA GCGA CTT-3’. The presence of the 878 (G→A) SNP gives rise to a FokI restriction site that distinguishes the two alleles: B10.S/SgMcdJ transfected cells and GTP transiently transfected into CHO cells using Lipofectamine. Two RAM or Imetit as the stimulator.

GTP was used as the control. Two days after transfection, the transfected culture plates and loaded with Fluo-3. Ligand-stimulated Ca2+ mobilization was monitored using FLIPR (Molecular Devices, Sunnyvale, CA).

**Table 5.** Predicted effects on inflammatory response function in H3RKO vs. WT LN after CFA+PTX treatment.

| Genes in dataset | Prediction | Fold Change | Findings       |
|------------------|------------|-------------|----------------|
| PBPP             | Increased  | 4.96        | Increases (15) |
| ELANE            | Increased  | 2.42        | Increases (1)  |
| S100A8           | Increased  | 2.80        | Increases (8)  |
| S100A9           | Increased  | 3.48        | Increases (9)  |
| PRRT3            | Increased  | 2.39        | Increases (2)  |
| CTSG             | Increased  | 2.75        | Increases (10) |
| MPO              | Increased  | 3.80        | Increases (1)  |
| SLPI             | 2.39       | Affects (2)  |
| FOS              | 2.04       | Affects (1)  |

Molecules differentially expressed in the pathway with the highest Z-score in Table 4, showing gene expression changes for individual molecules and the predicted impact on the associated annotated function (inflammatory response).

doi:10.1371/journal.pone.0062743.t005

**Functional Characterization of Hrh3 Alleles**

Radioligand competition binding assays were performed essentially as described [76]. Briefly, *Hhk1* and *Hhk3* isoforms in the samples. The copy number was then normalized to the internal control gene *mHPRT*. qPCR amplification efficiencies for *Hhk3a*, *Hhk3b*, *Hhk3c* isoform-specific primer sets were 92.5, 96.2, and 108.1%, respectively, with r2 values = 0.99.

**Hhr3 Expression by Cells of the Innate and Adaptive Immune Systems**

Alveolar macrophages were collected by lavaging the lungs through a tracheal cannula with 1 ml DPBS from which cells were collected, counted by hemocytometer, and differential analysis was performed by cytoospin and H&E stain. Nearly 100% of the cells were identified as alveolar macrophages in these preparations.

For the generation of bone marrow-derived dendritic cells (BMDC), bone marrow was flushed from the femurs and tibiae and cultured on 24-well plates at 1 x 10^6 cells/well (1 ml/well) in RPMI-1640 containing 10% serum and 10% conditioned media from X63-GMCSF myeloma cells transfected with murine GM-CSF CDNA (kindly provided by Dr. Brent Berwin, Dartmouth College). Media was replaced on days 2 and 4 and the adherent and lightly-adherent BMDCs, predominantly CD11b+CD11c+ by FACS, were collected on day 6.

For the preparation of neutrophils, the marrow was flushed from femurs and tibia with HBSS, layered atop a three-step Percoll gradient (72, 64, and 52%), and centrifuged at 1,060 g for 30 minutes. Samples of the 72:64% interface revealed greater than 95% morphologically mature-appearing neutrophils.

Resident mast cells were collected by lavaging the peritoneal cavity five times using 5ml of DPBS per lavage. The cells were layered atop a 75% Percoll solution and centrifuged at 600 g for 15 minutes at room temperature. Mast cells in the pellet were visualized by cytoospin to be greater than 90% pure. Naïve CD4+ (TCRβ*CD4*PDCA2+CD44HLA-CD1d-tetramer), memory CD4+ (TCRβ*CD4*PDCA2+CD44HLA-CD1d-tetramer), and NKT (CD1d-tetramer+) cells were sorted using the following surface anti-mouse mAbs: H57-597, eBioscience; anti-CD4 (MCD0417, Caltag); anti-CD25, anti-CD44, and anti-CD45RB (PG61, IM7, 16A; BD Pharmingen). CD1d tetramer was kindly provided by NIH. Sorted cells were kept at −80°C for subsequent RNA extraction.

Quantification of Hrh3 Isoform Expression

Mice were immunized with either (1) CFA; (2) CFA and 200 ng of PTX administered by i.v. injection immediately after the CFA injection; (3) 200 ng of PTX administered by i.v. injection or (4) 200 µg of PLP139–151 emulsified in CFA and 200 ng of PTX by i.v. injection immediately thereafter. All CFA injections were administered by equally distributing 0.1 ml emulsion over three sites (left and right flank and base of the tail). Mice were sacrificed on D1 and D10 post immunization.

For tissue collection, mice were anesthetized using Ketaset (Fort Dodge, IA) and perfused with 20 ml of phosphate buffer saline (PBS). Brain samples were snap frozen in liquid nitrogen and stored at −80°C until further processed for RNA isolation. Total RNA was extracted using RNeasy kit followed by a DNase treatment (Qiagen, Valencia, CA) according to the manufacturer’s guidelines. The reverse transcription of RNA was performed using the Superscript III RT kit (Invitrogen, Carlsbad, CA).

Probes for the three *Hhk3* isoforms were designed using the Primer Extension software (Applied Biosystems, Foster City, CA). All real-time PCR reactions were performed using an ABI prism 7900 HT sequence Detection system with the sequence detection software system SDS 2.2 in accordance with the manufacturer’s instructions, using Taqman chemistry. Standard curve assay, using serially diluted *Hhk3* isoform-specific plasmid clones as standards, was used to determine copy number of *Hhk3* isoforms in the samples. The copy number was then normalized to the internal control gene *mHPRT*. qPCR amplification efficiencies for *Hhk3a*, *Hhk3b*, *Hhk3c* isoform-specific primer sets were 92.5, 96.2, and 108.1%, respectively, with r2 values = 0.99.
Total RNA was extracted using an RNeasy isolation kit (Qiagen Inc.). mRNA was reverse transcribed using Superscript III reverse transcriptase (Invitrogen). The generated cDNA was used in qRT-PCR using an Hrk3 probe (Mm 004146706_m1; Applied Biosystems). β2-microglobulin and Hprt were used as reference genes and the relative expression levels were calculated using the comparative threshold cycle (Ct) method.

Microarray Analysis
Microarray analysis was conducted on female and male C57Bl/6 WT or H3RKO mice at 8 weeks of age. Mice in the treatment groups were injected with either with CFA or CFA+PTX, and euthanized at 24h. LN were removed from C57Bl/6 WT and H3RKO mice at 8 weeks, snap frozen in liquid nitrogen. Isolation and purification of RNA was completed using the RNeasy RNA extraction kit (Qiagen).

RNA amplification and microarray analysis was performed at UVM microarray core facility using manufacturer’s described protocols [78]. Briefly, 2 ug of total RNA from each sample were reverse transcribed to the single stranded cDNA using T7-oligo(dT) primer. T4 DNA polymerase was used to synthesize double-stranded cDNA, which served as a template for in vitro transcription using T7 DNA polymerase to produce biotinylated cRNA. The biotinylated cRNAs were fragmented into 50- to 200-base fragments and then hybridized to GeneChip Mouse Genome 430A 2.0 Arrays for 16 h at 45°C in a rotating Affymetrix GeneChip Hybridization Oven 320. After hybridization, arrays were washed and stained with streptavidin-phycoerythrin on an automated Affymetrix GeneChip Fluidic Station F450. The arrays were scanned with an Affymetrix GeneChip Scanner 2700 and the images quantified using Affymetrix GeneChip GeneExpressions version 6.6 (Copyright © 2009, Partek Inc., St. Louis, MO, USA). Microarray datasets were uploaded to the Gene Expression Omnibus repository, accession number GSE44873.

The signal intensity for each probe on each chip was calculated from scanned images using GeneChip Operating Software (Affymetrix), and signal intensities were analyzed using BioConductor (http://www.bioconductor.org). Probe intensities were background corrected, normalized, and summarized using the Robust Multichip Average algorithm described by Speed and coworkers [79,80], including background-correction, normalization, and summarization for each probe set and sample, using Partek Genomic Suites® version 6.6 (Copyright © 2009, Partek Inc., St. Louis, MO, USA). Microarray datasets were uploaded to the Gene Expression Omnibus repository, accession number GSE44873.

Sample quality was assessed based on the 3’:5’ ratio, relative log expression, and normalized unscaled standard error. Principal Component Analysis was used to screen for outlier samples that could potentially introduce latent variation into the analysis of differential expression across sample groups (none were detected).

To identify differentially expressed genes, linear modeling of sample groups was performed using ANOVA within Partek Genomic Suites. The magnitude of the response (fold change calculated using the least square mean) and the p-value associated with each probe set and binary comparison was calculated, as well as step-up, adjusted p-value for the purpose of controlling the false discovery rate [81,82]. Genes were considered to be differentially expressed when the signed fold change was greater than 2 and P<0.05.

Immunohistochemistry
After removing pancreatic, axillary, mesenteric, renal, cervical, and brachial LN as well as spleens, tissue was immediately fixed in 4% formaldehyde, 0.4% picric acid in 1xPBS o/n at 4°C. Tissue was then rinsed 3x for 15 min in PBS and cryoprotected o/n at 4°C in 30% sucrose in 1xPBS. Tissue was stored at −80°C in OCT prior to cryosectioning. Floating sections of colonic tissue from guinea pig gut (obtained in a previous study [75]), were used as positive tissue controls. Tissue was cryosectioned and collected slides and stored at −80°C prior to staining. Tissue was stained with rabbit anti-neuron specific enolase antiserum (Polysciences) diluted at 1:10,000 followed Cy3-conjugated goat anti-rabbit antibody (Jackson Immunoresearch) at 2.5 µg/ml.

Slides were analyzed with an Olympus AX70 fluorescence photomicroscope. Filter sets for Cy3 were 510 nm-550 nm excitation and 590nm emission. Images were captured with an Optronics Magnafire CCD camera, attached to the Olympus AX70 microscope. Images were cropped in Microsoft PowerPoint with minimal alteration (minor adjustments to brightness and contrast).

qRT-PCR Validation of Differentially Expressed Genes
WT and H3RKO mice were immunized subcutaneously with CFA, followed by i.v. injection of PTX. 24 hours later, draining LN were removed and snap frozen in liquid nitrogen. RNA was extracted using the RNeasy kit (Invitrogen) according to manufacturer’s instructions. cDNA was reverse transcribed using the Taqman Gold RT-PCR kit. qRT-PCR was performed using the DYNAamo ColorFlash SYBR green qPCR kit (Thermofisher) and previously described primer sets [71,83]. Ywhaz and Actb were used as reference genes and relative mRNA levels were calculated using the comparative Ct method, normalizing to the expression level in WT LN.

Acknowledgments
Additional appreciation to members of the Teuscher lab (past and present); Naresha Saligrama, Laure Case, Sean Diehl, Tony Spitzeck, Karen Spach, and Stan Call, members of the Mawe lab; Jill Hoffman and Elise Brooks for assistance with immunostaining, UVM COM Microscopy Imaging Center personnel: Doug Taatjes, Marilyn Wadsworth, Jan Schwartz. We also thank Dr. Jingcai Chen (Johnson & Johnson) for performing the pharmacological assays with Hrk3 alleles.

Author Contributions
Conceived and designed the experiments: DNK EHW RAM GMM JPB MEP EPB CT. Performed the experiments: DNK RAM MS RN RdR MEP. Analyzed the data: DNK EHW RAM GMM JPB MEP EPB CT. Performed the experiments: DNK RAM MS RN RdR MEP. Contributed reagents/materials/analysis tools: GMM. Wrote the paper: DNK EHW RAM CT.

References
1. Courtney AM, Treadaway K, Remington G, Frohman E. (2009) Multiple sclerosis. Med Clin North Am 93: 451–476, ix–x.
2. Dyment DA, Ebers GC, Sadovnick AD (2004) Genetics of multiple sclerosis. Lancet Neurol 3: 104–110.
3. Ramagopalan SV, Dyment DA, Ebers GC (2008) Genetic epidemiology: the use of old and new tools for multiple sclerosis. Trends Neurosci 31: 645–652.
4. Ebers GC (2008) Environmental factors and multiple sclerosis. Lancet Neurol 7: 268–277.
5. Weiner HL (2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 65: 239–248.
6. Rovaris M, Barkhof F, Calabrese M, De Stefano N, Fazekas F, et al. (2009) MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. Neurology 72: 1603–1701.
7. Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, et al. (2011) The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol 122: 155–170.
Histamine H3 Receptor Controls Immune Responses

8. Antel J, Antel S, Caramanos Z, Arnold DL, Kuhlmann T (2012) Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neurophysiol 123: 627–638.
9. Lasman H (2011) Review: the architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis. Neuropathol Appl Neurobiol 37: 698–710.
10. Prat A, Antel J (2005) Pathogenesis of multiple sclerosis. Curr Opin Neurol 18: 225–230.
11. Teuscher C, Subramanian M, Noubade R, Gao JF, Offer N, et al. (2007) Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS. Proc Nat Acad Sci U S A 104: 10146–10151.
12. Lovestone TW, Roland BL, Wilson SJ, Jiang X, Piay J, et al. (1999) Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 55: 1101–1107.
13. MacDermott AR, Role LW, Siegelbaum SA (1999) Presynaptic ionotropic receptors and the control of transmitter release. Annu Rev Neurosci 22: 443–485.
14. Regalwili W, Porcherie A, Schneider BS, Morisset S, Duhayle D, et al. (2009) Histamine H3 receptor-mediated signaling protects mice from cerebral malaria. PLoS One 4: e6090.
15. Hancock AA, Brune ME (2005) Assessment of pharmacology and potential anti-inflammatory properties of H3 receptor antagonists/inverse agonists. Expert Opin Investig Drugs 14: 233–241.
16. Butterfiel RJ, Subiela JD, Blankenhorn EP, Koengold R, Marina JC, et al. (1998) New genetic loci that control susceptibility and symptoms of experimental allergic encephalomyelitis in inbred mice. J Immunol 161: 1060–1067.
17. Butterfiel RJ, Blankenhorn EP, Roper RJ, Zachary JF, Doerge RW, et al. (2005) Genetic analysis of disease subtypes and sexual dimorphisms in mouse experimental allergic encephalomyelitis (EAE): relapsing/remitting and monophasic relapsing/nontrelapsing EAE are immunogenetically distinct. J Immunol 162: 3096–3102.
18. Encinas JA, Leo MB, Sobera R, Symonovicz C, Weiner HL, et al. (2001) Identification of genetic loci associated with paralysis, inflammation and weight loss in mouse experimental autoimmune encephalomyelitis. Int Immunol 13: 257–264.
19. Bakker RA (2004) Histamine H3-receptor isoforms. Inflamm Res 53: 599–516.
20. Drutel G, Peitsaro N, Karlstedt K, Wieland K, Smit MJ, et al. (2001) Identification of rat histamine H3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol 59: 1–8.
21. Butterfiel RJ, Leor GM, Miller TR, Baranzoli JL, Estvander BR, et al. (2007) An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activity. Pharmacol Exp Ther 323: 680–688.
22. Rosas-Ballina M, Tracey KJ (2009) The neurology of the immune system: neural reflexes regulate immunity. Neuron 64: 28–32.
23. Tracey KJ (2009) Reflex control of immunity. Nat Rev Immunol 9: 418–428.
24. Anderson U, Tracey KJ (2012) Neural reflexes in inflammation and immunity. J Exp Med 209: 1057–1063.
25. Ramagopalan SV, Dehaa GC, Degenhardt A, Ebers GC (2008) Genetic analysis of disease subtypes and sexual dimorphisms in mouse experimental allergic encephalomyelitis (EAE): relapsing/remitting and monophasic remitting/nontrelapsing EAE are immunogenetically distinct. J Immunol 162: 3096–3102.
26. Drutel G, Peitsaro N, Karlstedt K, Wieland K, Smit MJ, et al. (2001) Identification of rat histamine H3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol 59: 1–8.
27. Butterfiel RJ, Leor GM, Miller TR, Baranzoli JL, Estvander BR, et al. (2007) An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activity. Pharmacol Exp Ther 323: 680–688.
28. Rosas-Ballina M, Tracey KJ (2009) The neurology of the immune system: neural reflexes regulate immunity. Neuron 64: 28–32.
29. Tracey KJ (2009) Reflex control of immunity. Nat Rev Immunol 9: 418–428.
30. Anderson U, Tracey KJ (2012) Neural reflexes in inflammation and immunity. J Exp Med 209: 1057–1063.
31. Ramagopalan SV, Dehaa GC, Degenhardt A, Ebers GC (2008) Genetic analysis of disease subtypes and sexual dimorphisms in mouse experimental allergic encephalomyelitis (EAE): relapsing/remitting and monophasic remitting/nontrelapsing EAE are immunogenetically distinct. J Immunol 162: 3096–3102.
32. Tracey KJ (2009) Reflex control of immunity. Nat Rev Immunol 9: 418–428.
33. Coge F, Guenin SP, Audinot V, Renouard-Try A, Beauverger P, et al. (2001) Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS. Proc Nat Acad Sci U S A 104: 10146–10151.
34. Lovestone TW, Roland BL, Wilson SJ, Jiang X, Piay J, et al. (1999) Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 55: 1101–1107.
35. MacDermott AR, Role LW, Siegelbaum SA (1999) Presynaptic ionotropic receptors and the control of transmitter release. Annu Rev Neurosci 22: 443–485.
36. Regalwili W, Porcherie A, Schneider BS, Morisset S, Duhayle D, et al. (2009) Histamine H3 receptor-mediated signaling protects mice from cerebral malaria. PLoS One 4: e6090.
65. Szakal AK, Holmes KL, Tew JG (1983) Transport of immune complexes from the subcapsular sinus to lymph node follicles on the surface of nonphagocytic cells, including cells with dendritic morphology. J Immunol 131: 1714–1727.
66. Phan TG, Green JA, Gray EE, Xu Y, Cyster JG (2009) Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. J Immunol 210: 31–35.
67. Clark MA, Korte A, Myers J, Egan RW (1992) High affinity histamine H3 receptors regulate ACTH release by AtT-20 cells. Eur J Pharmacol 210: 336–338.
68. West RE Jr., Myers J, Zweig A, Siegel MI, Egan RW, et al. (1994) Steroid-sensitivity of agonist binding to pituitary cell line histamine H3 receptors. Eur J Pharmacol 267: 343–348.
69. Meng J, Ma X, Li M, Jia M, Lao X (2008) Histamine H4 receptors regulate ACTH release in AtT-20 cells. Eur J Pharmacol 587: 336–338.
70. Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, et al. (2003) Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 9: 287–293.
71. Perry CR, Burke ML, Stenzel DJ, McManus DP, Ramm GA, et al. (2011) Differential expression of chemokine and matrix re-modelling genes is associated with contrasting schistosome-induced hepatopathology in murine models. PLoS Negl Trop Dis 5: e1178.
72. Mathewes PM, Arnold DL (2001) Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution. Curr Opin Neurol 14: 279–287.
73. Minagar A, Jy W, Jimenez JJ, Alexander JS (2006) Multiple sclerosis as a vascular disease. Neurol Res 28: 230–233.
74. Toyota H, Dugovic C, Kochl M, Laposky AD, Weber C, et al. (2002) Behavioral characterization of mice lacking histamine H3 receptors. Mol Pharmacol 62: 389–397.
75. Hoffman JM, Tyler K, MacEachern SJ, Balemba OB, Johnson AC, et al. (2012) Activation of colonic mucosal 5-HT4 receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 142: 844–854 e194.
76. Chen J, Liu C, Lovenberg TW (2003) Molecular and pharmacological characterization of the mouse histamine H3 receptor. Eur J Pharmacol 467: 57–65.
77. Liu C, Eriste E, Sutton S, Chen J, Roland B, et al. (2003) Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. J Biol Chem 278: 56754–56764.
78. Affymetrix (2005–2006) GeneChip® Expression Analysis Technical Manual.
79. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185–193.
80. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
81. Benjamini Y, Darai D, Elmer G, Kaftani N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279–284.
82. Hochberg YBaY (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 57: 289–300.
83. Zhou Y, Jiang L, Rui L (2009) Identification of MUP1 as a regulator for glucose and lipid metabolism in mice. J Biol Chem 284: 11132–11139.